Impact of c-erb2 status on survival after high dose chemotherapy in high-risk breast cancer patients

Saudi Medical Journal

Volumn 28, Issue 9, 2007, Pages 1374-1379

  Kuzhan, Okan ^a   Ozet, Ahmet ^a   Ulitin, Cuneyt ^a   Kurt, Bulent ^a   Seref, Komurcu ^a   Ozturk, Bekir ^a   Ataergin, Selmin ^a   Gunhan, Omer ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL MOBILIZATION; TURKEY (REPUBLIC); BREAST TUMOR; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38849090867     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: Analysis of 716 consecutive patients. Cancer 2002; 41: 1170-1178.
2. Fisher E, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Project for Breast Cancer (protocol no. 4). Cancer 1984; 53: 712-723.
3. Rodenhuis S, Bontenbal M, Beex LVAM, Wagstaff J, Richel DJ, Nooij MA, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 1476-1479
4. Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic factor, predictive factor and target for therapy. Oncologist 1998; 3: 237-252.
5. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
6. Arpaci F, Komurcu S, Ozturk B, Ozet A, Kinalp C, Sengul A, et al. A successful and simplified filgrastim primed single apheresis method without large volume apheresis for peripheral blood stem cell collection. Jpn J Clin Oncol 2000; 30: 153-158.
7. Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, et al. Conventional adjuvant chemotherapy versus single-cycle autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial. J Natl Cancer Inst 2004; 96: 1076-1083.
8. Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, van de Vijver MJ, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in the operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up. Ann Oncol 2002; 13: 689-698.
9. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17-26.
10. Zander AR, Kruger W, Schmoor C, Kruger W, Mobus V, Frickhofen N, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 2004; 22: 2273-83.
11. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92: 225-233.
12. Roche H, Viens P, Biron P, Lotz JP, Asselain B; PEGASE Group. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 2003; 10: 42-47.
13. Coombes RC, Howell A, Emson M, Peckitt C, Gallagher C, Bengala C, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: Long-term results of an international randomised trial. Ann Oncol 2005; 16: 726-734.
14. Cottu PH, Cuvier C, Laurence V, Marolleau JP, de Roquancourt A, Makke J, et al. High-dose adjuvant chemotherapy for breast cancer: State of the art. Cancerfutures 2001; 0: 27-30.
15. Farquhar C, Marjoribanks J, Basser R, Lethaby A: High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for woman with early poor prognosis breast cancer (Review). The Cochrane Library 2006, Issue 4.
16. Zemzoum I, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022-1028.
17. Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, et al. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 2000; 18: 2070-2080.
18. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J. Her2/ neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 1996; 2: 1509-1513.